Deborah Di-Xin Zhou (Deborah D-X Zhou, Deborah Zhou)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Advanced Cancer

Radical Prostatectomy

Top Venues

JCO precision oncology

Future oncology (London, England)

BMJ case reports

This page only lists publications with an associated author ORCID identifier.

Publications

Rachel G Woodford, Deborah Di-Xin Zhou, Peey Sei Kok, Sally J Lord, Michael L Friedlander, Ian C Marschner, R John Simes, Chee Khoon Lee
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO precision oncology 8 (2024)
Rachel G Woodford, Deborah Di-Xin Zhou, Peey Sei Kok, Sally J Lord, Michael L Friedlander, Ian C Marschner, R John Simes, Chee Khoon Lee
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO precision oncology 8 (2024)
Deborah Di-Xin Zhou, Daniel King, Katie Thomson, Peter S Grimison
Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results. Asia-Pacific journal of clinical oncology 18 (5) (2022)
Deborah Di-Xin Zhou, Vivek Bhadri, Peter Luk, Sydney Ch'ng, Daniel Franks, Angela Hong
Left cheek sclerosing rhabdomyosarcoma and development of isolated free flap donor site metastasis. BMJ case reports 15 (4) (2022)
Rachel G Woodford, Deborah Di-Xin Zhou, Peey Sei Kok, Sarah Sally J Lord, Michael L Friedlander, Ian C Marschner, R John Simes, Chee Khoon Lee
The validity of progression-free survival 2 as a surrogate trial end point for overall survival. Cancer 128 (7) (2022)
Rachel G Woodford, Deborah Di-Xin Zhou, Sarah Sally J Lord, Ian C Marschner, Wendy Anne Cooper, Craig R Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future oncology (London, England) 18 (14) (2022)